-5%
Mirabegron, the active component of Betmira ER, is the first β3-adrenoceptor agonist that acts through a dual mechanism. It directly relaxes the bladder’s smooth muscle and modulates sensory nerve activity.
By stimulating β3-adrenoceptors, Mirabegron increases cyclic adenosine monophosphate (cAMP) levels, causing relaxation of the detrusor muscle during the bladder’s storage phase, which enhances bladder capacity and reduces symptoms of OAB.
Betmira ER Tablet is prescribed for the symptomatic management of urgency, frequent urination, and urge incontinence associated with Overactive Bladder (OAB) syndrome in adults.
Adults (including elderly):
Initial dose: 25 mg once daily, with or without food.
Based on individual response and tolerance, the dose may be increased to 50 mg once daily.
Renal or Hepatic Impairment:
In patients with severe renal impairment (ClCr/eGFR 15–29 mL/min/1.73m²) or moderate hepatic impairment (Child-Pugh Class B), the dose should not exceed 25 mg once daily.
Betmira ER is not recommended for patients with end-stage renal disease (GFR <15 mL/min/1.73m²), those on hemodialysis, or those with severe hepatic impairment (Child-Pugh Class C).
No dose adjustment is required based on gender.
Safety and efficacy have not been established in patients under 18 years of age.
Administration:
Take the tablet once daily with water. Swallow it whole—do not chew, crush, or divide.